Nexien BioPharma, Inc.
NXEN · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $8 | $1 | $5 | $4 |
| Short-Term Investments | $0 | $1,305,999 | $4,952,995 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $0 | $0 | $0 | $0 |
| Total Curr. Assets | $8 | $1,306,000 | $4,953,000 | $4 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $8 | $1,306,000 | $4,953,000 | $4 |
| Liabilities | – | – | – | – |
| Payables | $83 | $73 | $68 | $53 |
| Short-Term Debt | $375 | $351 | $328 | $312 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $0 | $423,996,576 | $396,703,603 | $0 |
| Total Curr. Liab. | $459 | $423,997,000 | $396,704,000 | $365 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $459 | $423,997,000 | $396,704,000 | $365 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $7 | $7 | $7 | $7 |
| Retained Earnings | -$11,636 | -$11,605,949,000 | -$11,566,477,000 | -$11,534 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $11,178 | $11,183,269,169 | $11,174,737,161 | $11,166 |
| Total Equity | -$451 | -$422,691,000 | -$391,751,000 | -$361 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $8 | $1,306,000 | $4,953,000 | $4 |
| Net Debt | $367 | $350 | $323 | $308 |